Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008

Abstract

Background:

The American Joint Commission on Cancer (AJCC) identifies five rare variants of prostate adenocarcinoma: mucinous, ductal, signet ring cell, adenosquamous and neuroendocrine including small cell. No prior study has comprehensively detailed incidence and outcomes for all AJCC variants of prostate cancer.

Methods:

We used the Surveillance, Epidemiology and End Results (SEER) program to analyze prostate cancers diagnosed from 1973 to 2008. Cases of mucinous, ductal, signet ring cell, adenosquamous and neuroendocrine carcinoma were identified, along with cases of non-variant adenocarcinoma for comparison. Age-adjusted incidence rates (IRs) and overall survival (OS) were evaluated and stratified by race, age, stage and PSA. All IRs represent the number of cases per million people per year.

Results:

Each variant is rare, with IRs between 0.03 (adenosquamous) and 0.61 (mucinous). There was a significant difference in incidence between Caucasian and African American patients with mucinous adenocarcinoma. Median OS varied ranged from 10.0 months in neuroendocrine carcinoma to 125.0 months in mucinous adenocarcinoma. In all, 5-year OS ranged from 12.6% in neuroendocrine carcinoma to 75.1% in mucinous adenocarcinoma. There was a significant difference in survival between Caucasian and African American patients for mucinous adenocarcinoma (median survival 144.0 vs 99.0 months, P<0.01). African American patients with mucinous adenocarcinoma also presented with more advanced stage disease compared with Caucasian patients. Multivariate analysis demonstrated that African American race was not associated with worse survival when corrected for stage.

Conclusions:

There are differences in IRs and OS among rare variants of prostate cancer. For mucinous adenocarcinoma, there are significant differences in incidence and survival between Caucasian and African American patients. These differences should be considered in clinical decision making for patients with these malignancies.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Seigel R, Ward E, Brawley O, Jemal A . Cancer Statistics, 2011. CA Cancer J Clin 2011; 61: 212–236.

    Article  Google Scholar 

  2. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). The AJCC Staging Manual, 7th edn. New York, NY, Springer, 2007.

    Google Scholar 

  3. Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute. Available from: http://seer.cancer.gov/.

  4. ICD-0-3: International Classification of Diseases for Oncology, 3rd edn. Geneva: World Health Organization, 2000.

  5. Epstein JH, Lieberman PH . Mucinous adenocarcinoma of the prostate gland. Am J Surg Pathol 1985; 4: 299–308.

    Article  Google Scholar 

  6. Osunkoya AO, Nielsen ME, Epstein JI . Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol 2008; 3: 468–472.

    Article  Google Scholar 

  7. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC . Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15 year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555–565.

    Article  CAS  Google Scholar 

  8. Millar EK, Sharma NK, Lessels AM . Ductal (endometrioid) carcinoma of the prostate: a clinicopathological study of 16 cases. Histopathology 1996; 29: 11–19.

    Article  CAS  Google Scholar 

  9. Hertell JD, Humphrey PA . Ductal adenocarcinoma of the prostate. J Urol 2011; 186: 277–278.

    Article  Google Scholar 

  10. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A et al. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer 2009; 115: 2872–2880.

    Article  Google Scholar 

  11. Warner JN, Nakamura LY, Pacelli A, Humphreys MR, Castle EP . Primary signet ring cell carcinoma of the prostate. Mayo Clin Proc 2010; 85: 1130–1136.

    Article  CAS  Google Scholar 

  12. Abbas F, Civantos F, Benedetto P, Soloway MS . Small cell carcinoma of the bladder and prostate. Urology 1995; 46: 617–630.

    Article  CAS  Google Scholar 

  13. Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 2007; 110: 1729–1737.

    Article  Google Scholar 

  14. Parwani AV, Kronz JD, Genega EM, Gaudin P, Chang S, Epstein JI . Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am J Surg Pathol 2004; 5: 651–657.

    Article  Google Scholar 

  15. Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montironi R . Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int 2008; 102: 1369–1374.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D M Marcus.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marcus, D., Goodman, M., Jani, A. et al. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis 15, 283–288 (2012). https://doi.org/10.1038/pcan.2012.4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2012.4

Keywords

Search

Quick links